Pertuzumab (breast cancer) - Benefit assessment according to '35a Social Code Book V 1 Translation of Sections I 1 to I 6 of the dossier assessment Pertuzumab (Mammakarzinom, adjuvant) – Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung) (Version 1.0; Status: 23 December 2022). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. A22-103 Pertuzumab (breast cancer, adjuvant) – Benefit assessment according to §35a Social Code Book V1 (expiry of the decision) Extract of dossier assessment A22-103 Version 1.0 Pertuzumab (breast cancer, adjuvant) 23 December 2022 Institute for Quality and Efficiency in Health Care (IQWiG) - i
Pertuzumab/trastuzumab (breast cancer) - Benefit assessment according to '35a Social Code Book V 1 Translation of Sections I 1 to I 6 of the dossier assessment Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) – Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung) (Version 1.0; Status: 23 December 2022). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. A22-102 Pertuzumab/trastuzumab (breast cancer, adjuvant) – Benefit assessment according to §35a Social Code Book V1 (expiry of the decision) Extract of dossier assessment A22-102 Version 1.0 Pertuzumab/trastuzumab ( breast cancer, adjuvant) 23 December 2022 Institute
Trastuzumab deruxtecan alone or with pertuzumab for previously untreated HER2-postive metastatic breast cancer 16 DECEMBER 2024 Trastuzumab deruxtecan alone or with pertuzumab for previously untreated HER2-postive metastatic breast cancer Trastuzumab deruxtecan, alone or in combination with pertuzumab, is in clinical development for previously untreated human epidermal growth receptor 2 (HER2 BRIEFINGS Trastuzumab deruxtecan adjuvant treatment of high-risk HER2-positive, residual invasive breast cancer after neoadjuvant therapy SEPTEMBER 2024 TECHNOLOGY BRIEFINGS Pertuzumab biosimilar with trastuzumab and chemotherapy neoadjuvant and adjuvant therapy for early stage and locally advanced HER2-positive breast cancer JULY 2024 TECHNOLOGY BRIEFINGS Abemaciclib with fulvestrant for HR+/HER2
Pertuzumab biosimilar with trastuzumab and chemotherapy neoadjuvant and adjuvant therapy for early stage and locally advanced HER2-positive breast cancer Pertuzumab biosimilar with trastuzumab and chemotherapy neoadjuvant and adjuvant therapy for early stage and locally advanced HER2-positive breast cancer - NIHR Innovation Observatory * Who we are * What we do * Our Networks * Engage * Events * Resources * Contact 23 July 2024 Pertuzumab biosimilar with trastuzumab and chemotherapy neoadjuvant and adjuvant therapy for early stage and locally advanced HER2-positive breast cancerPertuzumab biosimilar is in clinical development for the adjuvant and neoadjuvant treatment of invasive early stage or locally advanced breast cancer (BC) that is human epidermal growth factor 2 (HER2) positive
Pertuzumab + trastuzumab (Phesgo) by subcutaneous injection, in certain types of breast cancer Prescrire IN ENGLISH - Spotlight ''In the May issue of Prescrire International: Pertuzumab + trastuzumab (Phesgo°) by subcutaneous injection, in certain types of breast cancer'', 1 May 2022 {1}##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1}##LOC[OK]####LOC[Cancel]## Register online| Log in| My * Testimonials * Prescrire events * A global network Offers * Subscribe now * Solidarity Subscription Rate * Subscribers: register online * Prescrire's other products * Free Special Edition * Sign up to receive the newsletter english.prescrire.org > Spotlight > 100 most recent > In the May issue of Prescrire International: Pertuzumab + trastuzumab (Phesgo°) by subcutaneous injection, in certain
Pertuzumab/trastuzumab (breast cancer, first line) - Benefit assessment according to §35a Social Code Book V 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Pertuzumab/Trastuzumab (Mammakarzinom, metastasiert/lokal rezidiviert; in Kombination mit Docetaxel) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 28 April 2021 ). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. A21-09 Pertuzumab/trastuzumab (breast cancer, metastatic/locally recurrent; in combination with docetaxel) – Benefit assessment according to §35a Social Code Book V1 Extract
Pertuzumab/trastuzumab (breast cancer, neoadjuvant) - Benefit assessment according to §35a Social Code Book V 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Pertuzumab/Trastuzumab (Mammarkarzinom, neoadjuvant) – Nutzenbewertung gemäß § 35a SGB V ( Version 1.0; Status: 28 April 2021). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. A21-10 Pertuzumab/trastuzumab (breast cancer, neoadjuvant) – Benefit assessment according to §35a Social Code Book V1 Extract of dossier assessment A21-10 Version 1.0 Pertuzumab/trastuzumab (breast cancer, neoadjuvant) 28 April
Pertuzumab/trastuzumab (breast cancer, adjuvant) - Benefit assessment according to §35a Social Code Book V 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 28 April 2021). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. A21-11 Pertuzumab/trastuzumab (breast cancer, adjuvant) – Benefit assessment according to §35a Social Code Book V1 Extract of dossier assessment A21-11 Version 1.0 Pertuzumab/trastuzumab ( breast cancer, adjuvant) 28 April 2021
De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial A previous phase 2 trial showed promising outcomes for patients with HER2-positive early-stage breast cancer using neoadjuvant de-escalation chemotherapy with paclitaxel, trastuzumab, and pertuzumab. We aimed to evaluate the efficacy of weekly nab-paclitaxel compared with the standard regimen of docetaxel plus carboplatin, both with trastuzumab and pertuzumab, as neoadjuvant therapies for patients with HER2-positive breast cancer. HELEN-006 was a multicentre, randomised, phase 3 trial done at six hospitals in China. We enrolled patients aged 18-70 years
pertuzumab - Perjeta - Early stage breast cancer Skip to main contentAboutCollaboration/OutreachPatient/CommunityCareersContactMy CADTHFRReportsResourcesProvide InputSubmit a RequestNews & EventsWhat Does The Evidence Say About...SearchBreadcrumbHome Reimbursement Reviews pertuzumabCopied to clipboard pertuzumab( Last Updated : April 28, 2022)Reimbursement ReviewAbout CADTH Reimbursement : PerjetaProject Line: Reimbursement ReviewProject Number: PC0241-000Tumour Type: BreastNOC Status at Filing: Post NOCDetailsManufacturer Requested Reimbursement Criteria1: Pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either >2 cm in diameter or node positive). Patients
Pertuzumab and trastuzumab (Phesgo) - breast cancer 1 Product update SMC2364 pertuzumab and trastuzumab 600mg/600mg and 1,200mg/600mg solution for injection (Phesgo®) Roche Products Limited In confidence 04 June 2021 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following an abbreviated submission pertuzumab/trastuzumab (Phesgo®) is accepted for restricted use within NHSScotland. Indication under review: Early breast cancer (EBC) In combination with chemotherapy in: • the neoadjuvant treatment of adult patients with HER2-positive, locally advanced
Package advice pertuzumab and trastuzumab (Phesgo) for the treatment of breast cancer Package advice pertuzumab and trastuzumab (Phesgo®) for the treatment of breast cancer | Report | National Health Care Institute Go to content You are here: Home Publications Package advice pertuzumab and trastuzumab (Phesgo®) for the treatment of breast cancer Search within English part of National Health Care Institute Search Package advice pertuzumab and trastuzumab (Phesgo®) for the treatment of breast cancerZorginstituut Nederland has completed its assessment whether the fixed combined dose of pertuzumab and trastuzumab (Phesgo®) can be included in the insured package. The reason for this advice was the placing of Phesgo® in the so-called lock procedure for expensive medications. Phesgo® is a subcutaneous
Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial Trastuzumab-pertuzumab (HP) plus taxane is a current standard first-line therapy for recurrent or metastatic human epidermal growth factor 2 (HER2)+ breast cancer (BC). We
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks). The randomized phase 2 Neo-peaks study examined usefulness of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) following docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) as compared with the standard TCbHP regimen. We previously reported that pCR rate after neoadjuvant therapy tended to be higher with TCbHP followed by T-DM1 + P. We conducted an exploratory analysis of prognosis 5 years after surgery. Neoadjuvant treatment with TCbHP (6 cycles; group A), TCbHP (4 cycles) followed by T-DM1 + P (4 cycles; group B), and T-DM1 + P
QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, This randomized, parallel-controlled, double-blinded, phase III equivalence study evaluated the equivalence of a proposed pertuzumab biosimilar QL1209 to the pertuzumab (Perjeta®) each with trastuzumab and docetaxel in neoadjuvant treatment of early or locally advanced breast cancer patients with HER2-positive, ER/PR-negative. Eligible patients were randomly (1:1) assigned to receive 4 cycles of neoadjuvant QL1209 or pertuzumab each with trastuzumab and docetaxel, and adjuvant treatment. The primary endpoint was total pathologic complete
A fixed-dose combination of pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo) for the treatment of early and metastatic breast cancer A fixed-dose combination of pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) for the treatment of early and metastatic breast cancer. Update February 2021 - Repository of AIHTA GmbH English | Deutsch Atom RSS 1.0 RSS 2.0 * Simple search * Advanced search * Help * Services * Login * Browse * Type * Subject * Author / Editor * Institution * YearAIHTA - Publications - Search - A fixed-dose combination of pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) for the treatment of early and metastatic breast cancer. Update February 2021 Grössmann, N.(2021):A fixed-dose combination of pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM
Pertuzumab (Perjeta) - In combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC) at high risk of recurrence. Published 7 September 2020 1 SMC2284 pertuzumab 420mg concentrate solution for infusion (Perjeta®) Roche Products Ltd 07 August 2020 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a resubmission assessed under the orphan medicine process pertuzumab (Perjeta®) is accepted for restricted use within
Cost minimization analysis of treatments for metastatic HER2-positive breast cancer in Peru: Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injections. The main objective of this study is to determine whether the employment of fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC; and Phesgo as brand name) to treat metastatic HER2 -positive breast cancer patients would minimize costs compared to the traditional treatment of separate intravenous doses of pertuzumab and trastuzumab in Peru. To achieve this, we used EsSalud (the social security health insurance) data and assessed it through a mixed strategy, which consisted of a quantitative and a qualitative approach. The first one aimed to calculate the direct (non-drug consumables